Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02270645
Other study ID # 20120815
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2014
Est. completion date November 2017

Study information

Verified date October 2018
Source University of Miami
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Laser therapy for basal cell carcinoma may be a superior option for patients who do not wish to or cannot tolerate other treatment modalities such as topical chemotherapeutics or surgery.

In this pilot study, we will preliminarily assess the efficacy and safety of the 595/1064 nm Multiplex laser when treating superficial and nodular basal cell carcinomas less than 1.5 cm in size. This is an unblinded study in which patients will be randomized to either a treatment arm or a control arm. Patients in the treatment arm will receive three treatments with the 595/1064 nm multiplex laser spaced four weeks apart. The control group will visit the clinic with the same schedule as the treatment group for monitoring of the lesion. All patients will return one month after last treatment session or clinical visit, for evaluation of clinical and histological clearance.


Description:

Basal cell carcinoma is a malignancy with significant prevalence that rarely metastasizes but can be locally destructive. Laser therapy for this type of lesion may be a superior option for patients who do not wish to or cannot tolerate other modalities such as topical chemotherapeutics or surgery.

In this pilot study, we will preliminarily assess the efficacy and safety of the 595/1064 nm Multiplex laser when treating superficial and nodular basal cell carcinomas less than 1.5 cm in size. Eligible patients with biopsy-proven superficial or nodular BCCs less than 1.5 cm in size will have the opportunity to enroll in this study. This is an unblinded study in which patients will be randomized to either a treatment arm or a control arm. Patients in the treatment arm will receive three treatments with the 595/1064 nm multiplex laser spaced four weeks apart. In addition to assessing the presence of any adverse effects, photographs will be taken at each visit. One month after the last treatment session, patients in this group will return for evaluation of 1) clinical clearance and 2) histological clearance of their BCC. In order to assess clinical clearance, a dermatologist will grossly examine, measure, and document any residual lesion. Afterwards, a deep excisional biopsy encompassing the entire region will be taken and histological clearance will be determined by a microscopic examination for any residual tumor cells. Follow-up for wound care of the biopsy will occur one week later. Tumor burden will be calculated by change in surface area of the lesion.

After standard diagnostic biopsy, patients in the control arm will be followed for three regular visits, spaced 4 weeks apart. One month after the third follow-up visit, control patients will return for final photography and evaluation of clinical and histological clearance, just as the treatment arm. Although extremely rare1, if any clinical signs of progression are visible during this period (what we will consider greater than 10% growth), the patient will be withdrawn from the study and will undergo standard of care treatment.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date November 2017
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adults age 18 years or older

- Diagnostic biopsy must be no later than three months prior to enrollment

- Lesion is biopsy-proven nodular or superficial BCC

- BCC is 1.5 cm or less in diameter

- BCC is on trunk or extremities

- Fitzpatrick skin types I, II, III, or IV

- If female, must no longer be of child-bearing potential

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- BCC is greater than 1.5 cm in size

- If location of BCC is on the face.

- Patients whose biopsy shows a subtype other than superficial or nodular, or has characteristics of a more aggressive nature, such as: Basosquamous basal cell carcinoma, Morpheaform/ infiltrative basal cell carcinoma, Sclerosing basal cell carcinoma, Recurrent basal cell carcinomas

- Patients who may not be able to tolerate light therapy, such as: Patients with seizure disorders triggered by light, Patients who have or are currently receiving gold therapy, Patients with any light sensitive disorder, Patients taking medication that increases sensitivity to light, Patients with Systemic Lupus Erythematous

- Fitzpatrick skin types V or VI

- Patients who are taking certain oral medications such as: Anticoagulants except for aspirin 81 mg, Isotretinoin (currently or within last 6 months), Medications that alter wound healing

- Patients who have a history of Herpes Simplex Virus outbreak in the area to be treated

- Patients whose lesion has been previously, or is currently being, treated by another modality (topical immunomodulators/ chemotherapeutics, cryotherapy, curettage and electrodesiccation, surgical excision, or Mohs micrographic surgery)

Study Design


Intervention

Device:
595/1064 multiplex laser
595/1064 multiplex laser will be used 3 times spaced by a four week interval (+/- 3 days), it will be administered in an outpatient clinic setting.

Locations

Country Name City State
United States University of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center Miami Florida

Sponsors (1)

Lead Sponsor Collaborator
University of Miami

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Lesions Cleared Histologically Number of lesions cleared clinically and histologically. The lesion clearance was determined by measuring the size of lesion which also included a histological evaluation 4 weeks after the treatment. 91 days
Secondary Number of Adverse Events Reported Adverse events reported by participants 91 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04552990 - Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma Phase 2
Active, not recruiting NCT03573401 - Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). Phase 3
Completed NCT03012009 - Laser Assisted Drug Delivery in the Treatment of Superficial Non Melanoma Skin Cancer: a Randomized Controlled Trial N/A
Completed NCT00469417 - Metvix PDT Versus Cryotherapy in Patients With Primary Superficial Basal Cell Carcinoma Phase 3
Recruiting NCT05381597 - 5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer Phase 2/Phase 3
Terminated NCT00994240 - Cure Rates of Superficial Basal Cell Carcinoma (BCC) EDC N/A
Completed NCT00604890 - Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma Phase 1/Phase 2
Completed NCT00189306 - Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream Phase 3
Recruiting NCT05157763 - A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma Phase 1/Phase 2
Recruiting NCT04744935 - Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma N/A
Completed NCT05628714 - A Patient Decision Aid for Patients With Superficial Basal Cell Carcinoma
Completed NCT00432185 - To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC Phase 2
Recruiting NCT01491711 - Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Phase 4
Completed NCT04470726 - Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma Phase 1/Phase 2
Completed NCT01325688 - PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities Phase 2
Recruiting NCT05713760 - Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults Phase 2